Frontiers in Molecular Biosciences (May 2021)
Potential Role of Hsp70 and Activated NK Cells for Prediction of Prognosis in Glioblastoma Patients
- Dominik Lobinger,
- Dominik Lobinger,
- Jens Gempt,
- Wolfgang Sievert,
- Wolfgang Sievert,
- Melanie Barz,
- Sven Schmitt,
- Sven Schmitt,
- Huyen Thie Nguyen,
- Huyen Thie Nguyen,
- Stefan Stangl,
- Stefan Stangl,
- Caroline Werner,
- Caroline Werner,
- Fei Wang,
- Fei Wang,
- Zhiyuan Wu,
- Zhiyuan Wu,
- Hengyi Fan,
- Hengyi Fan,
- Hannah Zanth,
- Hannah Zanth,
- Maxim Shevtsov,
- Maxim Shevtsov,
- Maxim Shevtsov,
- Mathias Pilz,
- Mathias Pilz,
- Isabelle Riederer,
- Melissa Schwab,
- Melissa Schwab,
- Jürgen Schlegel,
- Gabriele Multhoff,
- Gabriele Multhoff
Affiliations
- Dominik Lobinger
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Dominik Lobinger
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Jens Gempt
- Department of Neurosurgery, School of Medicine, Technical University Munich (TUM), School of Medicine, Munich, Germany
- Wolfgang Sievert
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Wolfgang Sievert
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Melanie Barz
- Department of Neurosurgery, School of Medicine, Technical University Munich (TUM), School of Medicine, Munich, Germany
- Sven Schmitt
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Sven Schmitt
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Huyen Thie Nguyen
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Huyen Thie Nguyen
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Stefan Stangl
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Stefan Stangl
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Caroline Werner
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Caroline Werner
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Fei Wang
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Fei Wang
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Zhiyuan Wu
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Zhiyuan Wu
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Hengyi Fan
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Hengyi Fan
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Hannah Zanth
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Hannah Zanth
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Maxim Shevtsov
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Maxim Shevtsov
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Maxim Shevtsov
- Institute of Cytology of the Russian Academy of Sciences, St. Petersburg, Russia
- Mathias Pilz
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Mathias Pilz
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Isabelle Riederer
- Department of Neuroradiology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Melissa Schwab
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Melissa Schwab
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- Jürgen Schlegel
- Department of Neuropathology, Technical University Munich (TUM), Munich, Germany
- Gabriele Multhoff
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany
- Gabriele Multhoff
- Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
- DOI
- https://doi.org/10.3389/fmolb.2021.669366
- Journal volume & issue
-
Vol. 8
Abstract
Despite rapid progress in the treatment of many cancers, glioblastoma remains a devastating disease with dismal prognosis. The aim of this study was to identify chaperone- and immune-related biomarkers to improve prediction of outcome in glioblastoma. Depending on its intra- or extracellular localization the major stress-inducible heat shock protein 70 (Hsp70) fulfills different tasks. In the cytosol Hsp70 interferes with pro-apoptotic signaling pathways and thereby protects tumor cells from programmed cell death. Extracellular Hsp70 together with pro-inflammatory cytokines are reported to stimulate the expression of activatory NK cell receptors, recognizing highly aggressive human tumor cells that present Hsp70 on their cell surface. Therefore, intra-, extracellular and membrane-bound Hsp70 levels were assessed in gliomas together with activatory NK cell receptors. All gliomas were found to be membrane Hsp70-positive and high grade gliomas more frequently show an overexpression of Hsp70 in the nucleus and cytosol. Significantly elevated extracellular Hsp70 levels are detected in glioblastomas with large necrotic areas. Overall survival (OS) is more favorable in patients with low Hsp70 serum levels indicating that a high Hsp70 expression is associated with an unfavorable prognosis. The data provide a first hint that elevated frequencies of activated NK cells at diagnosis might be associated with a better clinical outcome.
Keywords